Grassley Launches Inquiry Into Orphan Drugs After KHN Investigation
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
Showing 121 - 127 of 127
-
-
The Orphan Drug Machine
KHN Video: Orphan Drugs Creating Gold Rush For Pharmaceutical Firms
The designation, which is made by the Food and Drug Administration, allows drugmakers to claim seven years of market exclusivity.
By Sarah Jane Tribble and Francis Ying -
The Orphan Drug Machine
Sky-High Prices For Orphan Drugs Slam American Families And Insurers
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
-
The Orphan Drug Machine
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed multiple times, an investigation shows.
By Sarah Jane Tribble and Sydney Lupkin -
FDA’s Drug Approval Team Copes With 700 Unfilled Jobs As Industry Lures Staff
The FDA’s drug-approval team is short more than 700 people and losing skilled staff members to the drug industry.
By Sydney Lupkin and Sarah Jane Tribble -
The Orphan Drug Machine
A Golden Ticket That Fast-Tracks A Drug Through The FDA
A voucher awarded to companies that find treatments for rare childhood diseases can be sold to the highest bidder — and then used to speed up approvals for much more common drugs.
-
Study Says Concerns About Orphan Drug Spending Are Unjustified
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.
Sign Up For Our Newsletter
Stay informed by signing up for the Morning Briefing and other emails: